GlassScriptPhysician profile
Shamil C Castro
NPI 1568808574
$11,961.33
in general payments reported to CMS, 2019-2025
39 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $1,906 · 2021: $1,724 · 2022: $1,795 · 2023: $1,632 · 2024: $1,760 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,802.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,238.18 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,108.86 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $918.91 | 2019-2025 | |
| Amgen INC. | $793.94 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $741.92 | 2021-2025 | Qulipta |
| Glaxosmithkline, LLC. | $700.00 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $665.76 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.09 | 2019-2025 | Jardiance |
| Abbott Laboratories | $387.57 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $373.17 | 2020-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $364.36 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $273.60 | 2019-2023 | Steglatro, Belsomra |
| Amarin Pharma, INC. | $228.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $194.65 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamil Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.